Literature DB >> 10071072

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.

H G Drexler, R A MacLeod, C C Uphoff.   

Abstract

The Philadelphia (Ph) chromosome, the main product of the (9;22)(q34;q11) translocation, is the cytogenetic hallmark of chronic myeloid leukemia (CML), a clonal myeloproliferative disorder of the hematopoietic stem cell; the Ph chromosome is also found in a sizeable portion of acute lymphoblastic leukemia (ALL) patients and in a small number of acute myeloid leukemia (AML) cases. At the molecular level, the t(9;22) leads to the fusion of the BCR gene (on chromosome 22) to the ABL gene (translocated from chromosome 9); this fusion gene BCR-ABL with its elevated tyrosine kinase activity must to be central to the pathogenesis of these disorders. Three different breakpoint cluster regions are discerned within the BCR gene on chromosome 22: M-bcr, m-bcr, and mu-bcr. Ph + leukemia cell lines are important tools in this research area. More than 20 ALL-and more than 40 CML-derived Ph + leukemia cell lines have been described. Furthermore, three Ph + B-lymphoblastoid cell lines, established from patients with Ph + ALL or CML, are available. Molecular analysis has documented BCR-ABL fusion genes in three apparently Ph chromosome-negative cell lines, all three derived from CML. Nearly all Ph + ALL cell lines have the m-bcr e1-a2 fusion gene (only two ALL cell lines have a b3-a2 fusion) whereas all CML cell lines, but one carry the M-bcr b2-a2, b3-a2 or both hybrids. The mu-bcr e19-a2 has been detected in one CML cell line. Four cell lines display a three-way translocation involving chromosomes 9, 22 and a third chromosome. Additional Ph chromosomes (up to five) have been found in four Ph + ALL cell lines and in 18 CML cell lines; though in some cell lines the extra Ph chromosome(s) might be caused by the polyploidy (tri- and tetraploidy) of the cells. Another modus to acquire additional copies of the BCR-ABL fusion gene is the formation of tandem repeats of the BCR-ABL hybrid as seen in CML cell line K-562. Both mechanisms, selective multiplication of the der(22) chromosome and tandem replication of the fusion gene BCR-ABL, presumably lead to enhanced levels of the fusion protein and its tyrosine kinase activity (genetic dosage effect). The availability of a panel of Ph + cell lines as highly informative leukemia models offers the unique opportunity to analyze the pathobiology of these malignancies and the role of the Ph chromosome in leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071072     DOI: 10.1016/s0145-2126(98)00171-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.

Authors:  Sarah E Alford; Anisha Kothari; Floris C Loeff; Joshua M Eichhorn; Nandini Sakurikar; Henriette M Goselink; Robert L Saylors; Inge Jedema; J H Frederik Falkenburg; Timothy C Chambers
Journal:  Cancer Res       Date:  2015-02-03       Impact factor: 12.701

2.  BCR-ABL1 expression in multiple myeloma cells: a case of mistaken identity?

Authors:  Roderick A F MacLeod; Stefan Nagel; Wilhelm Dirks; Hans G Drexler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

3.  Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene.

Authors:  Phan Nguyen Thanh Van; Phan Thi Xinh; Yasuhiko Kano; Katsushi Tokunaga; Yuko Sato
Journal:  Hum Cell       Date:  2005-03       Impact factor: 4.174

4.  Enzymatic-based cytometry, a sensitive single-cell cytometric method to assess BCR-ABL1 activity in CML.

Authors:  Jinzhu Yu; Ki Oh; Sitapriya Moorthi; Ling Li; Helmut H Strey; Michael Schuster; Chiara Luberto; Phenix-Lan Quan; Eric Brouzes
Journal:  Lab Chip       Date:  2020-03-03       Impact factor: 6.799

Review 5.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

6.  Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Authors:  P O Pietarinen; T Pemovska; M Kontro; B Yadav; J P Mpindi; E I Andersson; M M Majumder; H Kuusanmäki; P Koskenvesa; O Kallioniemi; K Wennerberg; C A Heckman; S Mustjoki; K Porkka
Journal:  Blood Cancer J       Date:  2015-05-01       Impact factor: 11.037

7.  New Samarium(III), Gadolinium(III), and Dysprosium(III) Complexes of Coumarin-3-Carboxylic Acid as Antiproliferative Agents.

Authors:  Irena Kostova; Georgi Momekov; Peya Stancheva
Journal:  Met Based Drugs       Date:  2007

Review 8.  Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia.

Authors:  Kalubai Vari Khajapeer; Rajasekaran Baskaran
Journal:  Leuk Res Treatment       Date:  2015-12-03

9.  Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.

Authors:  Zhimin Tan; Aixia Peng; Jingwen Xu; Mingwen Ouyang
Journal:  BMC Anesthesiol       Date:  2017-09-29       Impact factor: 2.217

10.  Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.

Authors:  Niclas Björn; Tejaswi Venkata Satya Badam; Rapolas Spalinskas; Eva Brandén; Hirsh Koyi; Rolf Lewensohn; Luigi De Petris; Zelmina Lubovac-Pilav; Pelin Sahlén; Joakim Lundeberg; Mika Gustafsson; Henrik Gréen
Journal:  NPJ Syst Biol Appl       Date:  2020-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.